Courtesy of Benzinga.
Bioniche Life Sciences (OTC: BNHLF) today announced that its purified
hyaluronate sodium product for horses – NexHA™ – has been approved by the U.S. Food and Drug Administration (FDA) for
sale in the U.S. The product was launched in Canada in December of last
year and will be launched in the U.S. next week at the American
Association of Equine Practitioners’ Annual Convention in Nashville,
Tennessee.
NexHA™ is a formulation of purified hyaluronate sodium that can be
administered to horses by intravenous or intra-articular injection. It
is indicated in the treatment of joint dysfunction of the carpus or
fetlock in horses due to non-infectious synovitis associated with
equine osteoarthritis. Hyaluronate sodium acts as a replacement for
synovial fluid, the naturally occurring lubricant in articular joints.
Joint degeneration is associated with the loss of synovial fluid, and
the lack of its lubricant effects results in considerable pain and
inflammation for the horse.
The Company has been developing different formulations of sodium
hyaluronate for the equine markets in Canada, Australia, Turkey, Hong
Kong, and New Zealand – sold as Enhance® –
